潜在的线粒体ROS介导的损伤由基托纳米颗粒诱导,蜂毒载入癌细胞系的蜜蜂毒
Azza G Kamel1, Salwa Sabet2, Ayman El-Shibiny3
1Center for Microbiology and Phage Therapy, Zewail City of Science and Technology, Giza 12578, Egypt.
International journal of biological macromolecules
|September 8, 2024
概括
装有蜜蜂毒液 (CNP-BV) 的基托桑纳米颗粒通过诱导癌细胞中的活性氧物种 (ROS) 显示出显著的抗癌作用. 这种ROS生成会触发线粒体损伤和ER压力,导致癌细胞死亡.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 癌症生物学 癌症生物学
背景情况:
- 素纳米颗粒 (CNP) 是癌症治疗的有效药物载体.
- 蜜蜂毒液 (BV) 具有抗瘤的特性.
- 活性氧物种 (ROS) 通过线粒体和ER压力调解癌细胞亡.
研究的目的:
- 为了研究 CNP 载荷 BV (CNP-BV) 对癌细胞的 ROS 中介作用.
- 阐明ROS生成对线粒体和ER在癌症治疗中的影响.
主要方法:
- 用CNP载入的蜜蜂毒素 (CNP-BV) 的制备和表征.
- 对MCF-7和HepG2癌细胞系的细胞毒性评估.
- 测量ROS生成,线粒体级联激活和ER压力诱导.
主要成果:
- CNP-BV对MCF-7 (IC50 437.2 μg/mL) 和HepG2 (IC50 109.5 μg/mL) 癌细胞具有较高的细胞毒性.
- 用CNP-BV治疗导致癌细胞大量产生ROS.
- 诱导的ROS激活了线粒体级联和ER压力,促进了亡.
结论:
- 通过ROS生成,CNP-BV有效地诱导癌细胞亡.
- 该研究强调了CNP-BV在癌症治疗中的治疗潜力,通过准ROS介导途径.
- ROS生成在CNP-BV的抗癌活性中发挥着关键作用.
相关概念视频
Electron Transport Chain: Complex I and II
12.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.2K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


